Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$87.98 USD
+0.52 (0.59%)
Updated May 24, 2024 04:00 PM ET
After-Market: $87.97 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$87.98 USD
+0.52 (0.59%)
Updated May 24, 2024 04:00 PM ET
After-Market: $87.97 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Zacks News
What's in Store for Option Care Health (OPCH) in Q3 Earnings?
by Zacks Equity Research
Option Care Health's (OPCH) Q3 results are likely to be driven by sustained strong utilization.
Intuitive Surgical (ISRG) Q3 Earnings Beat, Procedures Robust
by Zacks Equity Research
Intuitive Surgical's (ISRG) third-quarter results reflect healthy demand for procedures, partially offset by lower system sales. Higher pricing boosted procedure sales.
Teleflex (TFX) to Report Q3 Results: What to Know Ahead of the Release
by Zacks Equity Research
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Medical Product Stocks Set to Outpace Q3 Earnings Estimates
by Indrajit Bandyopadhyay
Medical Product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EW, PODD, DXCM and IQV are poised ahead of their earnings release.
Why Edwards Lifesciences (EW) Could Beat Earnings Estimates Again
by Zacks Equity Research
Edwards Lifesciences (EW) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Buy Edward Lifesciences (EW) Stock Now
by Zacks Equity Research
Investors remain optimistic about Edward Lifesciences (EW) on the strength of the Critical Care business and TAVR sales.
ITGR vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
ITGR vs. EW: Which Stock Is the Better Value Option?
ITGR or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ITGR vs. EW: Which Stock Is the Better Value Option?
Here's Why You Should Invest in Edward Lifesciences (EW) Now
by Zacks Equity Research
Investors continue to be optimistic about Edward Lifesciences (EW) on the strength of TAVR and a solid balance sheet.
ITGR vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
ITGR vs. EW: Which Stock Is the Better Value Option?
Do Options Traders Know Something About Edwards Lifesciences (EW) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Edwards Lifesciences (EW) stock based on the movements in the options market lately.
Edwards Lifesciences (EW) Down 9.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights Amazon.com, Cisco Systems, The Southern Company, Edwards Lifesciences and Ross Stores
by Zacks Equity Research
Amazon.com, Cisco Systems, The Southern Company, Edwards Lifesciences and Ross Stores are part of the Zacks top Analyst Blog.
Top Analyst Reports for Amazon.com, Cisco Systems & Southern Company
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Cisco Systems, Inc. (CSCO) and The Southern Company (SO).
Edwards Lifesciences (EW) Rides on TAVR Amid Rise in Costs
by Zacks Equity Research
Edwards Lifesciences' (EW) Surgical Structural Heart business growth is driven by increased penetration of its premium RESILIA products across all regions.
ITGR vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
ITGR vs. EW: Which Stock Is the Better Value Option?
Bruker (BRKR) Q2 Earnings and Revenues Top, '23 Sales View Up
by Zacks Equity Research
Bruker (BRKR) delivers better-than-expected earnings and revenues in the second quarter of 2023.
3 MedTech Stocks Likely to Top Estimates This Earnings Season
by Urmimala Biswas
MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EYE, CAH and HSIC are poised ahead of their earnings releases.
Acadia Healthcare (ACHC) Q2 Earnings Beat on Higher Admissions
by Zacks Equity Research
Acadia Healthcare's (ACHC) Q2 results indicate improved patient days and revenue per patient day. Management expects 2023 adjusted EPS of $3.25-$3.50.
Edwards Lifesciences (EW) Q2 Earnings Top Estimates, View Up
by Zacks Equity Research
The growing adoption of the PASCAL Precision system in Europe and the United States and Edwards' premium products across all regions have driven Edwards Lifesciences' (EW) Q2 revenues.
Compared to Estimates, Edwards Lifesciences (EW) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Edwards Lifesciences (EW) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Edwards Lifesciences (EW) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 1.54% and 1.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks' Q2 Earnings Due on Jul 26: DGX, TMO and More
by Urmimala Biswas
MedTech companies' second-quarter results are likely to reflect a year-over-year decline. Let's see how DGX, TMO, EW and ALGN fare this time.
AVNS vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
AVNS vs. EW: Which Stock Is the Better Value Option?
Analysts Estimate Integer (ITGR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Integer (ITGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.